FREEHOLD, NJ, April 11, 2018 (GLOBE NEWSWIRE) -- MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce a general update to shareholders.
Medifirst recently announced that it was in negotiations to bring its FDA cleared Time Machine Laser to the China Market. The Company signed a letter of Intent with Beijing Long Tan Lake Sports Industry (BLTS) and Investment Development LLC based in Beijing China for a five-year exclusive distribution agreement. The terms, which include a significant monetary investment into Medifirst, include a 10,000-unit order for the first year of the agreement. Commented CEO Bruce J. Schoengood, “As part of the due diligence process, we have submitted to BLTS our clinical data which includes studies, FDA 510(k) documentation and Intertek testing reports. Once BLTS completes its review of our documents, which includes an analysis of the CFDA (China FDA) registration process (though no assurances can be made), we anticipate signing a definitive agreement.”
Regarding international distribution, Medifirst has been in negotiations with several parties to expand into South Asia with its Time Machine Laser technology. The opioid crisis and the global epidemic of pain, especially with the aging population, presents a great opportunity for our therapeutic FDA cleared laser to help provide an all-natural solution for people suffering from chronic pain. Continued Schoengood, “Expansion into other countries is exciting and we are pursuing these opportunities very aggressively. It must be noted however, that the medical device registration for every country is different and each presents a lengthy process. We are making every effort to expedite these processes as we expand internationally. Medifirst anticipates an announcement in the upcoming days regarding further distribution expansion into this region.”
Medifirst is always seeking new opportunities for expansion including new products and services in the healthcare and medical sectors that can add value to the company. The Company anticipates related updates and announcements in the upcoming days and weeks.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.
Forward-Looking Statements:
The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.